Microcap Ledger Quince Therapeutics, Inc. $QNCX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- South San Francisco, CA
- Fiscal year end
- December 31
- Shares outstanding
- 1,017,063 [10-Q 2026-08-14]
What the company doesAI summary of filing
Quince Therapeutics is a biotechnology company that developed the AIDE technology platform, an automated drug-delivery system that encapsulates drugs into patients' own red blood cells. The company's lead asset, eDSP, encapsulated dexamethasone sodium phosphate and was being tested for treating ataxia-telangiectasia (A-T), a rare pediatric neurodegenerative disease. In January 2026, the company completed its pivotal Phase 3 NEAT trial, which did not meet its primary or secondary endpoints; based on these results, the company discontinued all development activities and has no other product candidates or sufficient resources to pursue further research and development. The company is currently a pre-revenue, clinical-stage company focused on evaluating strategic alternatives, including pursuing a reverse merger, to maximize shareholder value. [10-K 2026-04-10]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$39.58M | −$26.51M | $115.98M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$83.98M | −$41.42M | $5.81M | [DEF 14A 2026-08-25] |
| FY ended Dec 2024 | — | −$56.83M | −$31.90M | $6.21M | [DEF 14A 2026-08-25] |
- Quarterly cash burn
- −$13.26M
- Cash runway Estimate
- ~26.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-05 | 44,001,643 | [10-Q 2024-11-13] |
| 2025-03-13 | 44,001,643 | [10-K 2025-03-24] |
| 2025-05-06 | 45,468,782 | [10-Q 2025-05-13] |
| 2025-08-05 | 53,713,798 | [10-Q 2025-08-11] |
| 2025-11-06 | 55,681,490 | [10-Q 2025-11-12] |
| 2026-04-09 | 163,007,943 | [10-K 2026-04-10] |
| 2026-05-04 | 16,300,740 | [10-Q 2026-05-11] |
| 2026-08-07 | 1,017,063 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2026-07-31; declared effective 2026-08-24 [S-3 2026-07-31]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-04. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-04 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-04] |
| 2026-03-20 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-20] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | 8-K | Director or officer change; Charter, bylaws or fiscal year change; Regulation FD disclosure |
| 2026-10-06 | 8-K | Director or officer change; Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-10-02 | 8-K | Director or officer change |
| 2026-09-14 | 8-K | Acquisition or disposition completed; Director or officer change |
| 2026-09-04 | 8-K | Listing notice or transfer |
| 2026-08-27 | 8-K | Director or officer change |
| 2026-08-25 | DEF 14A | Proxy statement |
| 2026-08-17 | 8-K | Other events |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
Alerts for $QNCX
Email me when Quince Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.